We investigated the prevalence of dyskinesias and patients who had started treatment with a dopamine agonist had developed these treatment complications motor fluctuations, and the factors determining their occurrence, in a community-based population of later. Although a satisfactory response to medication was associated with higher rates of motor complications, poor patients with Parkinson's disease. Among 124 patients with Parkinson's disease, 87 (70%) had received a levoor moderate response was associated with lower quality of life in patients with a disease duration of ≤5 years or dopa preparation. Among these 87 patients, 28% were experiencing treatment-induced dyskinesias and 40% ≥10 years. We conclude that motor fluctuations are most strongly related to disease duration and dose of levodopa, response fluctuations. The prevalence of motor fluctuations was best predicted by disease duration and dose of and dyskinesias to duration of levodopa treatment. However, poorer quality of life associated with inadequate levodopa, whereas dyskinesias could be best predicted by duration of treatment. Patients with a shorter time from dosage of levodopa may be the price for a low rate of motor complications in patients with Parkinson's disease. symptom onset to initiation of levodopa and younger patients had developed motor complications earlier, and
Introduction
The occurrence of dyskinesias and motor fluctuations is a young), develop motor complications rapidly and severely (Ballard et al., 1985) . However, the prevalence of motor major problem in the long-term management of patients with Parkinson's disease. It has been estimated that after initiation complications in MPTP-treated animals also depends on the duration and dose of treatment with levodopa (Boyce et al., of treatment with levodopa,~10% of patients per year develop motor fluctuations (Marsden and Parkes, 1977) , and in clinic1990b; Arai et al., 1996) . In clinic-based samples of patients with Parkinson's disease, motor complications have been based studies~50% suffer these complications after 5 years of treatment (Sweet and McDowell, 1975; Dupont et al., 1996) .
shown to occur more frequently and earlier in patients with younger onset (Kostic et al., 1991) , and to increase with longer However, considerable controversy exists as to whether their occurrence is primarily related to the disease itself or to its disease duration and greater disease severity (Lesser et al., 1979; Tanner et al., 1985; Parkinson Study Group, 1996) . It treatment, and whether, as a consequence, treatment with levodopa should be delayed or kept at a low dose (Lees and Stern, has also been claimed that dyskinesias occur more frequently in women if disease duration is Ͼ5 years (Parkinson Study 1981; Fahn and Bressman, 1984; Markham and Diamond, 1986; Melamed, 1986; Poewe et al., 1986; Blin et al., 1988; Group, 1996; Lyons et al., 1998) . On the other hand, higher doses of levodopa (Barbeau, 1980; Lees and Stern, 1981; Roos et al., 1990; Cedarbaum et al., 1991; Montastruc et al., 1999; Weiner, 1999) . In animal studies the occurrence of motor Tanner et al., 1985) and longer duration of treatment (Miyawaki et al., 1997) have been found to be associated with higher rates complications is related to the degree of loss of dopaminergic neurones in the substantia nigra (Schneider, 1989; of these complications, and initiation of treatment with other antiparkinsonian drugs has resulted in lower rates or delayed 1990a), and patients with MPTP (1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine)-induced parkinsonism, who have severe appearance of motor fluctuations and dyskinesias (Lees and Stern, 1981; Rinne, 1987; Brannan and Yahr, 1995 ; Rascol depletion of nigral dopaminergic neurones (but are also et al., 2000) . However, many of these variables are related, and examination, and clinical details were collected during the diagnostic visit. All patients were questioned about the such as age of onset, disease duration, duration of treatment, disease severity and dose of levodopa. It is therefore difficult presence of oscillations in motor response, i.e. predictable wearing-off, unpredictable on-off fluctuations and sudden to determine which of these factors are most important for the development of motor complications. In addition, clinic-based off-periods, as defined in the Unified Parkinson's Disease Rating Scale (Fahn et al., 1987) , and involuntary movements samples are probably not representative of the overall population of patients with Parkinson's disease. They may be biased (peak-dose, diphasic and off-period) related to treatment and their time of first occurrence. Six patients in whom dyskinesias towards more severely affected or younger patients, or those with a higher rate of complications. Patients seen in specialist were noticed during the 3-h examination but had not been reported by the patient or carer, were included in the group neurological clinics are also more likely to be treated with high doses and more complex regimens of medication.
of patients with dyskinesias. Patients were also asked to complete a disease-specific quality of life instrument, the We therefore assessed the prevalence of motor fluctuations and dyskinesias in an unselected community-based sample PDQ39 quality of life questionnaire, from which a summary index was calculated (Peto et al., 1995) . In addition to patient of patients with Parkinson's disease, and investigated the influence of disease-and treatment-related variables on their interview and examination, the general practitioners' records were examined for details of the patients' medical history occurrence.
and medication, including time of diagnosis and initiation of treatment, as well as documentation of patient complaints and clinical findings. If the dose of antiparkinsonian treatment
Methods
One hundred and twenty-four patients, who were assessed in listed in the records differed from that which the patient and carer reported as actually taken, the dose reported by the a prevalence study of parkinsonism with the primary aim of differentiating different types of parkinsonism (Schrag et al., patient and carer was taken as the current dose. 1999), were examined and diagnosed with probable Parkinson's disease according to strict clinical diagnostic criteria (Gibb and Lees, 1989) . Patients with multiple system
Statistical analysis
atrophy and supranuclear palsy, vascular parkinsonism, drug-
The main analysis was performed on the subgroup of patients induced parkinsonism, and those with parkinsonism following who had received levodopa, and consisted mainly of dementia were excluded. The methods of patient calculating rates and proportions. The dataset was examined ascertainment and study design were reported previously to test the assumptions underlying parametric tests. Group (Schrag et al., 1999) . In brief, the records of 15 general differences were analysed by Student's t-test. Categorical practices in the London area were screened for patients with data were compared with the χ 2 -test, and Fisher's exact a suspicion of Parkinson's disease or parkinsonism, for test if the numbers were small. Pearson correlations were patients with tremor with onset after the age of 50 years, and calculated between variables. A statistical level of 5% was for patients who had ever received antiparkinsonian drugs. considered as significant in most analyses. However, in order As the health care system in the UK is organized locally, to take into account multiple comparisons between patients the population of a general practice is representative of the with and without dyskinesias and motor fluctuations, a surrounding area. In addition, the general practitioner acts as statistical threshold of P Ͻ 0.005 was considered to be a 'gatekeeper' of the National Health Service, so that sufficiently conservative for this analysis. Differences with patients are only referred to specialists by their general P Ͼ 0.005 and P Ͻ 0.1 were considered as a trend. In order practitioners. Overall, 241 patients fulfilled screening criteria to determine which factors contribute most to the prediction and participation prevalence was high (84%). Patients who of the occurrence of motor fluctuations and dyskinesias, we had declined were slightly older than those who participated performed forward stepping logistic regression analyses, (P Ͻ 0.05), but there was no significant sex difference. conducted using SPSS for Windows version 8.0. In these Among the 202 patients who were seen, a diagnosis of analyses, the presence or absence of dyskinesias or motor probable Parkinson's disease was made in 124. This number fluctuations were the dependent variables, and all variables differs from the number of patients with Parkinson's disease that had differed between those with and those without in the overall sample (Schrag et al., 2000) , which also complications at the 5% level were entered. included patients who could not be examined. The majority of patients had, on at least one occasion, seen a neurologist or a geriatrician with an interest in Parkinson's disease (92
Results

patients, 74%).
Prevalence of motor fluctuations and
All participating patients gave informed consent to participating in the study, which was approved by the
dyskinesias
The characteristics of all patients receiving levodopa are Ethics Committee of the Institute of Neurology and National Hospital for Neurology and Neurosurgery, London.
given in Table 1 . In the overall sample of patients with Parkinson's disease, 35 (29%) had experienced motor They had a semistructured general and neurological interview Wearing off had developed in 19% of patients treated for on a dopamine agonist 14 5 years or less, 44% of those treated for 6-9 years, and 100% of those treated for 10 or more years, whereas unpredictable PDQ ϭ quality of life questionnaire (Peto et al., 1995) .
on-off fluctuations had not developed in any of the patients with a treatment duration of 5 years or less, and were present fluctuations and 24 (19%) dyskinesias. Apart from one patient in 20% of those with a treatment duration of 6-9 years, and in whom levodopa had been discontinued due to psychiatric 50% of those with a treatment duration of 10 or more years. side-effects, all of these patients were currently taking a Sudden off-periods had occurred in 2, 8 and 33% of patients levodopa preparation. Among the patients who had received after treatment durations of five years or less, 6-9, and 10 levodopa (n ϭ 87, 70%), the rate of motor fluctuations was or more years, respectively. Peak-dose dyskinesias were 40% and that of dyskinesias 28%. If only the patients who present in 11% of patients with a treatment duration of 5 had an excellent or good response to levodopa (Ͼ50% years or less, 32% with a treatment duration of 6-9 years, improvement, subjective rating by patients and carers) were and 89% of patients with a treatment duration of 10 or more considered (n ϭ 38, 44% of levodopa-treated patients), the years. Off-period dystonia was reported by 2, 12 and 56% rates were 50 and 29%, respectively. Among patients of patients, respectively, and diphasic dyskinesias were receiving doses of Ͼ300 mg levodopa per day (n ϭ 44, 51%
reported by no patients with a disease duration of 5 years or of levodopa-treated patients), the rates were 61 and 41%, less, and 4 and 44% of those with a disease duration of 6-9, respectively. and 10 or more years, respectively. Patients with diphasic dyskinesias and off-period dystonia as well as wearing-off fluctuations had a younger age at onset (all P Ͻ 0.05).
Prevalence of motor complications by disease duration, treatment duration and Hoehn and Yahr stage Time to onset of complications
The mean time from symptom onset to development of The rates of occurrence of motor fluctuations and dyskinesias in levodopa-treated patients with a disease duration of 5 fluctuations, as reported by the patients, was 6.5 (SD ϭ 4.1) years, and to development of dyskinesias 6.7 (SD ϭ 3.1 ) years or less were 14 and 7%, respectively. After a disease duration of 6-9 years they had occurred in 39 and 18%, years. The mean time from start of levodopa to the onset of fluctuations and dyskinesias was 4.8 (SD ϭ 34) and 5.7 respectively, and after 10 or more years of disease they had occurred in 67 and 57%. These rates were lower if the overall (SD ϭ 2.7) years, respectively. The latency from onset of symptoms to development of sample including patients not on levodopa was considered, and greater when only those who had a good or excellent fluctuations and dyskinesias correlated positively with the time elapsed between onset and initiation of treatment with response to levodopa, or those with levodopa doses of Ͼ300 mg were considered (Table 2) . levodopa (r ϭ 0.59, P ϭ 0.02 and r ϭ 0.54, P ϭ 0.05, respectively). This could be due to a faster development of After a treatment duration of 5 years or less, 21 and 13% of patients on levodopa had developed fluctuations and motor complications because levodopa was given earlier, but also to more rapidly progressive disease warranting earlier dyskinesias, respectively, after 6-9 years of treatment 56 and 36%, and after 10 or more years all patients had developed introduction of levodopa in some patients. The patients with more rapidly progressive disease would then be expected to dyskinesias and motor fluctuations.
Motor complications had not occurred in patients on be more severely disabled after the same duration of disease. Thus, disease severity should be negatively correlated with levodopa with a Hoehn and Yahr stage of 1 or 1.5 (as assessed during the diagnostic visit), but 42% of those in time from onset to initiation of levodopa, when controlled for disease duration. However, we did not find such a also occurred later after the start of treatment (7.0 versus correlation (r ϭ 0.14, P ϭ 0.2), indicating that more rapidly 5.0 years) and after onset of symptoms (8.0 versus 6.0 years) progressive disease is not the explanation for the earlier in the patients who were started on a dopamine agonist than development of motor complications in patients treated sooner in those started on levodopa, but this difference did not reach with levodopa.
statistical significance (P ϭ 0.26 and P ϭ 0.32, respectively). Time from onset to development of motor complications No such differences were seen between patients started on was also positively associated with current age (r ϭ 0.76, other antiparkinsonian drugs and those starting treatment P ϭ 0.004 for dyskinesias, and r ϭ 0.30, P ϭ 0.27 for with levodopa. fluctuations), indicating that older patients develop dyskinesias later. Although greater age was also associated with lower doses of levodopa (r ϭ -0.30, P ϭ 0.005), age was still positively correlated with time from onset to Differences between patients with and without development of dyskinesias after adjusting for levodopa dose motor fluctuations and dyskinesias (r ϭ 0.78, P ϭ 0.005 for dyskinesias and r ϭ 0.29, P ϭ 0.3
Patients with motor fluctuations had significantly longer for fluctuations). Age at disease onset also correlated with disease duration, treatment duration, higher doses of time to onset of motor complications (r ϭ 0.82, P ϭ 0.05 levodopa, and tended to have longer time since diagnosis for dyskinesias, r ϭ 0.25, P ϭ 0.6 for fluctuations). Thus, than those without. They also had greater disability, as patients with younger age of onset tended to have dyskinesias measured by the Schwab and England scale, and tended to earlier than those with greater age of onset.
have greater disease severity, as measured by the Hoehn and Yahr scale, more often had a good response to levodopa, and were receiving a levodopa dose of Ͼ300 mg per day.
Patients initially treated with a dopamine
They also tended more often to have a family history of agonist parkinsonism in a first or second degree relative and to have One patient was treated with a dopamine agonist alone and the akinetic-rigid subtype of parkinsonism (Table 3 ). There had not developed dyskinesias or motor fluctuations after a was no difference in the use of antiparkinsonian medication disease duration of 4.5 years. Three patients had received a other than levodopa, but this may have been due to the dopamine agonist at the initiation of antiparkinsonian small number of patients with concomitant or alternative treatment, with levodopa added simultaneously or later. One
Parkinson's disease medication. of these patients had not developed motor complications after
Patients with dyskinesias had a significantly longer a disease duration of 2.9 years and a treatment duration of treatment duration and were more severely disabled than 2 years. The other two patients had developed motor those without. They tended to have longer disease duration, fluctuations after a disease duration of 7.4 and 12.6 years, greater disease severity and to have received a higher and a treatment duration of 7.2 and 10.8 years. They had levodopa dose, and more often reported falls than those developed dyskinesias after 3.2 and 12.8 years after onset of without dyskinesias (Table 3) . Men and women did not symptoms, and after 3 and 11 years of treatment. Thus, these differ significantly with respect to the occurrence of motor patients had a longer delay from beginning of treatment to fluctuations or dyskinesias, even when only those with a onset of motor fluctuations than those treated with levodopa treatment duration of Ͼ5 years were considered. Age, from the beginning (8.6 versus 3.7 years, P ϭ 0.02), symptom at onset, or time from onset to initiation of treatment and from onset of symptoms to first occurrence of motor fluctuations (10.3 versus 5.6 years, P ϭ 0.05). Dyskinesias did not differ between the groups. 
Logistic regression analysis
individually was a significant predictor of the occurrence of In order to understand the relationship of different variables dyskinesias. However, when all variables except disease to the occurrence of motor complications, we performed duration were entered as a group in the second block of a separate stepwise logistic regression analyses, taking hierarchical stepwise regression analysis, treatment duration dyskinesias and motor fluctuations as the target variables in significantly increased the power of the prediction of each case. dyskinesias (χ 2 ϭ 3.7, P ϭ 0.05). Thus, treatment duration Taking motor fluctuations as the dependent variable, the appears to be related to the occurrence of dyskinesias over only variable included in the regression equation using this and above duration of disease. method of variable entry was disease duration. No other disease-or treatment-related factor was a significant predictor of the occurrence of motor fluctuations. In a separate
Patients without motor complications after 10 or
hierarchical logistic regression analysis, treatment duration, more years of disease levodopa dose, response to treatment, family history of A subgroup of 10 levodopa-treated patients had not developed Parkinson's disease, disease severity and disability were motor fluctuations even after a disease duration of 10 years, entered as a second block of variables after disease duration and 13 patients had not developed dyskinesias. Among was entered as a covariate in the first block, but this set of patients with a disease duration of 10 or more years, those variables did not increase the predictive power of the equation.
without fluctuations had a shorter disease duration than those In a series of separate hierarchical logistic regression analyses, with fluctuations (P ϭ 0.05). Age, age at onset, treatment these variables were then entered individually in the second duration, Hoehn and Yahr stage, Schwab and England score, block, after controlling for disease duration in the first block. levodopa dose and sex were not significantly different The only variable that significantly increased the predictive between these patients and those who had developed motor power of the regression equation was dose of levodopa (χ 2 ϭ complications. 7.0, P ϭ 0.008). Using disease duration and dose of levodopa, 85% of patients without motor fluctuations were correctly
Quality of life
classified, compared with 55% of the patients with motor Quality of life was not significantly different between patients fluctuations; on average, 72% of patients were categorized with and without motor fluctuations and dyskinesias. correctly. As such, this set of variables appears to be However, when quality of life of patients was evaluated reasonably good at predicting the occurrence of motor according to response to treatment (which was associated fluctuations.
with higher doses of levodopa), it was significantly better in Using stepwise logistic regression with dyskinesias as the those with a good response to levodopa than in those with a dependent variable, the only variable included in the moderate or poor response in those with a disease duration regression equation was treatment duration. A correct of 5 or less or 10 or more years (both P Ͻ 0.05). classification of dyskinesias was possible in 88% (sensitivity 75, specificity 97%). When treatment duration was entered alone in the first block, no other variable increased the power Discussion of prediction further when entered in the second block either
The prevalence of both fluctuations and dyskinesias increased with increasing disease and treatment duration as well as together or separately. When disease duration was entered in advancing disease severity. Thus, no patient in Hoehn and disorder experts, also reported high rates of motor fluctuations and dyskinesias with~50 and 30% of patients, respectively, Yahr stage 1 or 1.5 had any motor complications, whereas Ͼ70% of those in stages 4 or 5 had motor fluctuations and developing these complications after treatment with levodopa for Ͻ2 years (Parkinson Study Group, 1996) . The differences 60% dyskinesias. Similarly, after a disease duration of 10 or more years, Ͼ60% had motor fluctuations, and Ͼ50% between these studies suggest that certain variables can influence the occurrence of motor fluctuations and dyskinesias dyskinesias.
These rates of motor complications are lower than rates on levodopa treatment. They have partly been attributed to different dosages of levodopa and the initial lack of use of of response fluctuations and dyskinesias in patients after the same disease and treatment durations in large clinic-based, peripheral decarboxylase inhibitor (Barbeau, 1980; Lees and Stern, 1981; Poewe et al., 1986; Block et al., 1997) , as well cross-sectional (Cedarbaum et al., 1991; Fahn, 1992; Miyawaki et al., 1997) and longitudinal (Parkinson Study as the prior or concomitant use of other medication, such as dopamine agonists (Rinne, 1987; Hely et al., 1994; Group, 1996) studies. Patients in these studies, which may be biased towards younger subjects or those with more severe Montastruc et al., 1994; Brannan and Yahr, 1995) . Age at onset, age, sex, time from onset to initiation of levodopa and disease, also used higher mean doses of levodopa. To our knowledge, no comparable data are available on the rate of severity of disease may also influence the occurrence of dyskinesias (Pederzoli et al., 1983; de Jong et al., 1987 ; Blin dyskinesias in an unselected population of patients with Parkinson's disease, and only one study has previously et al., 1988; Kostic et al., 1991; Parkinson Study Group, 1996; Lyons et al., 1998) . In the present study we found that provided community-based data on the occurrence of motor fluctuations (Tandberg et al., 1995) . In that study, which also duration of disease and treatment as well as dose of levodopa were associated with a higher occurrence of motor included patients not receiving levodopa, the rate of motor fluctuations was 21%, and in those classified as 'definite complications, whereas age, sex and age at symptom onset were not different between those with and those without Parkinson's disease', who were required to have had a good response to levodopa, 28%. Although this prevalence is fluctuations or dyskinesias. However, younger patients and patients with younger age at onset had developed dyskinesias similar to our rate of 28% in the overall group of patients with Parkinson's disease, it is considerably lower than our sooner than older patients or those with greater age at onset, whereas there was no significant correlation between time to rate in the subgroup of patients receiving levodopa, despite a higher mean dose of levodopa and longer mean disease onset of motor fluctuations and age or age at onset. Earlier treatment with levodopa was associated with earlier and treatment duration in our study. Although there is no obvious explanation for this, it may be due to methodological development of motor complications and, although numbers were small, treatment with a dopamine agonist was associated differences in case ascertainment, diagnostic classification and a different definition of fluctuations, which was not with a longer delay to the onset of motor fluctuations. This finding, in a community-based sample, supports the results specified further in the cited paper. In our study, we took great care even to include patients in the group with motor of the recent large, double-blind and prospective studies that found a delay to the onset of motor complications in early fluctuations who had noticed only mild wearing off.
It is generally believed that dyskinesias and motor Parkinson's disease in patients treated with dopamine agonists compared with those treated with levodopa alone. Thus, it fluctuations develop in~50% of patients on treatment with levodopa after 5 years (Lang and Lozano, 1998) , whereas was recently reported from a large, double-blind trial over 5 years that the risk of developing dyskinesias was the relationship of the occurrence of dyskinesias to duration of levodopa treatment is less clear (Fahn and Bressman, 1984) .
substantially reduced in patients receiving the dopamine agonist ropinirole (if necessary complemented with However, the rates of these complications on antiparkinsonian treatment reported in the literature vary greatly, ranging from levodopa), compared with those treated with levodopa from the outset (20 versus 45%, P Ͻ 0.0001; Rascol et al., 2000) . 19 to 80% of patients experiencing fluctuations after 5 or 6 years of treatment with levodopa (Poewe et al., 1986;  In another 3-year, double-blind study of the occurrence of motor complications in patients treated with pergolide Brannan and Yahr, 1995) , and from 0 to 66% developing dyskinesias during the first year of treatment (Barbeau, 1980;  compared with patients treated with levodopa, the 1-year interim analysis showed that the time to onset of motor Brannan and Yahr, 1995) . A prospective study comparing standard release and controlled release levodopa/carbidopa complications was significantly longer with pergolide (P ϭ 0.038; Hundemer et al., 2000) . Lower rates of motor (Block et al., 1997) found fluctuations or dyskinesias in only 20% (patient rated) or 16% (observer rated) of patients after complications compared with levodopa therapy were also seen in patients with early Parkinson's disease treated with 5 years in either treatment arm, whereas another study comparing standard and sustained release levodopa/ the dopamine agonist pramipexole (with or without additional levodopa) for 2 years (28 versus 51%, P Ͻ 0.0001; Shoulson, benserazide (Dupont et al., 1996) found motor fluctuations in~60% and dyskinesias in~40% of patients after 5 years 2000) and with cabergoline in a 5-year study (5 versus 32%, Musch et al., 2000) . of treatment in both treatment arms. The DATATOP study, in which a large cohort of patients with Parkinson's disease Patients with a positive family history of parkinsonism also tended to have motor complications more often than were followed with regular appointments by movement those without. Although no other features were different response to medication. Thus, although not experiencing motor complications, which were mild in the great majority between those with and without a family history of parkinsonism, this may indicate that a subgroup of patients of patients, these patients were failing to derive adequate benefit from medication, which resulted in poorer quality with genetically determined parkinsonism has a higher propensity to develop these motor complications of treatment.
of life. We believe that these results can be generalized to the When we accounted for the interrelations of these diseaseor treatment-related variables by using stepwise logisitic overall population of patients with Parkinson's disease, as we evaluated an unselected sample, and endeavoured to regression analysis, and entered all variables that differed between patients with and without motor complications, we achieve high diagnostic accuracy, which was the primary aim of the study (Schrag et al., 1999) . However, as this was found that disease duration and dose of levodopa were the best predictors for the occurrence of motor fluctuations. On a cross-sectional assessment rather than a longitudinal followup study, it has two main limitations: first, the drug treatment the other hand, dyskinesias were best predicted by treatment duration alone. Age or symptom at onset, current age, sex of patients was not adjusted in a uniform way as they were under the care of many different clinicians, and secondly and or family history did not contribute further to the prediction of motor fluctuations or dyskinesias. However, the sensitivity most importantly, most of the information was reported retrospectively by the patients themselves or derived from of the prediction of dyskinesias was only slightly more than 50%, indicating that other variables, not identified in this the records of their general practitioners. In particular, patients were not examined before the start of treatment, the time of study, have additional influence on their occurrence. The importance of treatment-related factors for the development onset of complications was reported by the patients themselves and their carers, and the majority of patients of motor complications is supported by a number of further findings: (i) a shorter time from onset to treatment with were only assessed on one or two occasions. In six cases, dyskinesias were noticed by the examiner, but were not levodopa was associated with earlier motor complications, which could not be adequately explained by more rapid reported by the patients or carers. It is thus possible that the frequency of motor fluctuations or mild dyskinesias in this disease progression; (ii) patients treated with a dopamine agonist from the outset developed motor complications later cross-sectional study may thus have been underestimated, and that the onset of these complications might have occurred than those treated with levodopa alone; (iii) the prevalence of motor fluctuations and dyskinesias was lower than that earlier than reported. In summary, we found that, among patients treated with reported in clinic-based samples receiving higher doses of levodopa after a similar disease duration (Dupont et al., levodopa, response fluctuations and dyskinesias had developed in~40 and 30%, respectively. These rates increased 1996; Parkinson Study Group, 1996; Miyawaki et al., 1997) ; (iv) the rate of motor complications was higher in the with disease duration and severity, but they were also strongly related to treatment-related factors, such as duration and dose subgroup of patients on levodopa than in the overall sample of patients with Parkinson's disease with the same disease of levodopa. Earlier treatment with levodopa as well as younger age were associated with earlier development of duration (since no patient who had not received levodopa experienced these complications), and even greater in those motor complications, and initial treatment with a dopamine agonist, in a small number of patients, was associated with patients who had a good response to levodopa or received Ͼ300 mg levodopa per day despite similar disease severity; a later onset of motor complications. However, less effective treatment and poorer quality of life associated with inadequate (v) the difference in treatment duration between patients with and without dyskinesias was greater than the difference in dosage of levodopa may be the price to pay for a low rate of motor complications in patients with Parkinson's disease. disease duration. All these findings indicate that, although disease duration is an important factor in the development of motor complications, earlier and longer treatment with, as well as higher doses of levodopa are associated with a higher
